Dianthus (DNTH) CAO Edward Carr Exercises Options, Sells Shares

What Happened

• Edward (Ed) Carr, Chief Accounting Officer of Dianthus Therapeutics (DNTH), exercised 20,000 shares at $17.88 on Sept 17, 2026 (cash paid: $357,600) and sold a total of 20,000 shares in multiple open-market transactions the same day for aggregate proceeds of approximately $2,027,645.
• The filing also reports a separate 20,000-share derivative conversion/transaction listed at $0.00 (no cash proceeds) in the Form 4; the filing includes a vesting note for the related option award.

Key Details

• Transaction date: September 17, 2026; Form 4 filed September 18, 2026 (filed next day; appears timely).
• Exercise: 20,000 shares exercised at $17.88 — total cost $357,600.
• Sales: 20,000 shares sold across multiple trades — weighted sale proceeds $2,027,645. Reported weighted-average sale prices and ranges:
  • 7,928 shares — weighted avg $100.43 (range $99.98–$100.97) (F2)
  • 6,771 shares — weighted avg $101.37 (range $100.99–$101.95) (F3)
  • 3,501 shares — weighted avg $102.39 (range $101.99–$102.95) (F4)
  • 1,100 shares — weighted avg $103.20 (range $103.05–$103.38) (F5)
  • 700 shares — weighted avg $104.39 (range $104.17–$104.63) (F6)
• 10b5-1 plan: The trades were made pursuant to a Rule 10b5-1 trading plan adopted June 18, 2026 (F1).
• Vesting detail: The underlying option award vests in equal monthly installments over four years after Jan 1, 2024 (F7).
• Shares owned after transaction: Not specified in the excerpt provided; see the full Form 4 for updated holdings.
• The $0.00 derivative disposition is shown on the filing but no cash proceeds are reported; the filing should be consulted for the issuer-level explanation.

Context

• This is an option exercise followed by same-day open-market sales — effectively converting exercised option shares into cash. Because the trades were executed under a pre-established 10b5-1 plan, they were scheduled in advance and are typically considered routine rather than an ad-hoc signal about company prospects.
• For retail investors, purchases generally carry more direct informational value than routine insider sales. If you want full detail (per-price breakdowns or post-transaction holdings), request the complete Form 4 or contact the issuer as the footnotes commit to provide per-price sale breakdowns on request.